PAD 0193 (Indomethacin extended release 75 mg)
Pill imprint PAD 0193 has been identified as Indomethacin extended release 75 mg.
Indomethacin is used in the treatment of gout, acute; back pain; ankylosing spondylitis; bartter syndrome; cluster headaches (and more), and belongs to the drug class nonsteroidal anti-inflammatory agents. Prior to 30 weeks gestation: Risk cannot be ruled out during pregnancy. Starting at 30 weeks gestation: There is positive evidence of human fetal risk during pregnancy. Indomethacin 75 mg is not a controlled substance under the Controlled Substance Act (CSA).
- PAD 0193
- 75 mg
- Prescription only
- Drug Class:
- Nonsteroidal anti-inflammatory agents
- Pregnancy Category:
- C - Risk cannot be ruled out - prior to 30 weeks gestation
D - Positive evidence of risk - starting at 30 weeks gestation
- CSA Schedule:
- Not a controlled drug
- Paddock Laboratories, Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- carboxymethylcellulose sodium
sodium starch glycolate type A potato
More about indomethacin
- Indomethacin capsules
- Indomethacin suppositories
- Indomethacin suspension
- Indomethacin sustained-release capsules
- More (3) »
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.